Lara Ambrosi1, Shaheer Khan2, Richard D Carvajal3, Jessica Yang3. 1. Stony Brook SOM, 101 Nicholls Rd, Stony Brook, NY, 11794, USA. 2. Division of Hematology/Oncology, Columbia University Medical Center, 177 Fort Washington Ave, MHB 6GN-435, New York, NY, 10032, USA. sk4488@cumc.columbia.edu. 3. Division of Hematology/Oncology, Columbia University Medical Center, 177 Fort Washington Ave, MHB 6GN-435, New York, NY, 10032, USA.
Abstract
PURPOSE OF REVIEW: In this article, we will briefly review the current treatment landscape for metastatic melanoma and provide a comprehensive update on emerging novel treatment strategies. RECENT FINDINGS: Over the past decade, remarkable advances in immunotherapy and targeted therapy have greatly improved outcomes for patients with advanced melanoma. Although a subset of patients is able to achieve durable responses, the majority experience eventual disease progression on existing therapies. Trials evaluating novel combinatorial strategies, checkpoint inhibitors, immune agonists, T cell-based therapies, intratumoral agents, and others are ongoing. While strides have been made in the treatment of advanced melanoma, further research is needed to identify alternative immune and molecular targets in order to overcome resistance and achieve better clinical outcomes.
PURPOSE OF REVIEW: In this article, we will briefly review the current treatment landscape for metastatic melanoma and provide a comprehensive update on emerging novel treatment strategies. RECENT FINDINGS: Over the past decade, remarkable advances in immunotherapy and targeted therapy have greatly improved outcomes for patients with advanced melanoma. Although a subset of patients is able to achieve durable responses, the majority experience eventual disease progression on existing therapies. Trials evaluating novel combinatorial strategies, checkpoint inhibitors, immune agonists, T cell-based therapies, intratumoral agents, and others are ongoing. While strides have been made in the treatment of advanced melanoma, further research is needed to identify alternative immune and molecular targets in order to overcome resistance and achieve better clinical outcomes.
Authors: Gerty Schreibelt; Kalijn F Bol; Harm Westdorp; Florian Wimmers; Erik H J G Aarntzen; Tjitske Duiveman-de Boer; Mandy W M M van de Rakt; Nicole M Scharenborg; Annemiek J de Boer; Jeanette M Pots; Michel A M Olde Nordkamp; Tom G M van Oorschot; Jurjen Tel; Gregor Winkels; Katja Petry; Willeke A M Blokx; Michelle M van Rossum; Marieke E B Welzen; Roel D M Mus; Sandra A J Croockewit; Rutger H T Koornstra; Joannes F M Jacobs; Sander Kelderman; Christian U Blank; Winald R Gerritsen; Cornelis J A Punt; Carl G Figdor; I Jolanda M de Vries Journal: Clin Cancer Res Date: 2015-12-28 Impact factor: 12.531
Authors: David S Hong; Razelle Kurzrock; Jennifer J Wheler; Aung Naing; Gerald S Falchook; Siqing Fu; Kevin B Kim; Michael A Davies; Ly M Nguyen; Goldy C George; Lucy Xu; Robert Shumaker; Min Ren; Jennifer Mink; Cynthia Bedell; Corina Andresen; Pallavi Sachdev; James P O'Brien; John Nemunaitis Journal: Clin Cancer Res Date: 2015-07-13 Impact factor: 12.531
Authors: Clive S Zent; Timothy G Call; Deborah A Bowen; Michael J Conte; Betsy R LaPlant; Thomas E Witzig; Stephen M Ansell; George J Weiner Journal: Leuk Lymphoma Date: 2015-03-17
Authors: Andrea Ladányi; Beáta Somlai; Katalin Gilde; Zsuzsanna Fejös; István Gaudi; József Tímár Journal: Clin Cancer Res Date: 2004-01-15 Impact factor: 12.531
Authors: S A Rosenberg; J R Yannelli; J C Yang; S L Topalian; D J Schwartzentruber; J S Weber; D R Parkinson; C A Seipp; J H Einhorn; D E White Journal: J Natl Cancer Inst Date: 1994-08-03 Impact factor: 13.506
Authors: Rikke B Holmgaard; Dmitriy Zamarin; Yanyun Li; Billel Gasmi; David H Munn; James P Allison; Taha Merghoub; Jedd D Wolchok Journal: Cell Rep Date: 2015-09-24 Impact factor: 9.423
Authors: Vinod P Balachandran; Michael J Cavnar; Shan Zeng; Zubin M Bamboat; Lee M Ocuin; Hebroon Obaid; Eric C Sorenson; Rachel Popow; Charlotte Ariyan; Ferdinand Rossi; Peter Besmer; Tianhua Guo; Cristina R Antonescu; Takahiro Taguchi; Jianda Yuan; Jedd D Wolchok; James P Allison; Ronald P DeMatteo Journal: Nat Med Date: 2011-08-28 Impact factor: 53.440
Authors: Anna Tyumentseva; Anton Averchuk; Nadezhda Palkina; Ivan Zinchenko; Anton Moshev; Andrey Savchenko; Tatiana Ruksha Journal: Front Oncol Date: 2021-12-03 Impact factor: 6.244